Nintedanib in ovarian cancer.

View/ Open
Date
2017-09Author
Khalique, S
Banerjee, S
Type
Journal Article
Metadata
Show full item recordAbstract
Introduction Advanced ovarian cancer remains an unmet clinical need. Angiogenesis is considered a therapeutic target in ovarian cancer, with bevacizumab, a monoclonal antibody against VEGF, being the first drug to show a progression-free survival benefit. Nintedanib is an oral tyrosine kinase inhibitor targeting VEGF receptor 1-3, FGFR 1-3 and PDGFR α and β, which has entered phase III trial development in ovarian cancer. Areas covered: This article reviews the preclinical and clinical efficacy of nintedanib in ovarian cancer, its pharmacokinetic and pharmacodynamics profile, safety issues, together with an overview of clinical trials carried out so far. A literature search was made in PubMed for nintedanib, ovarian cancer, angiogenesis, and on ClinicalTrials.gov site for clinical trials with nintedanib. Expert opinion: An ongoing phase III trial investigating nintedanib combined with first-line chemotherapy in ovarian cancer has shown a statistically significant progression free survival benefit, although there were toxicity issues. The true clinical benefit of nintedanib in ovarian cancer including its optimal treatment setting and dosage still need to be addressed.
Collections
Subject
Animals
Humans
Ovarian Neoplasms
Neovascularization, Pathologic
Indoles
Angiogenesis Inhibitors
Antineoplastic Agents
Disease-Free Survival
Female
Research team
Functional Genomics
Language
eng
License start date
2017-09
Citation
Expert opinion on investigational drugs, 2017, 26 (9), pp. 1073 - 1081